| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rare Diseases | 3 | 2020 | 360 | 0.820 |
Why?
|
| Genes, erbB-2 | 5 | 2007 | 227 | 0.580 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2020 | 3416 | 0.560 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 1337 | 0.530 |
Why?
|
| Receptor, ErbB-2 | 6 | 2021 | 2658 | 0.430 |
Why?
|
| Biomarkers, Tumor | 9 | 2021 | 10713 | 0.400 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2021 | 1385 | 0.370 |
Why?
|
| Gene Amplification | 5 | 2007 | 764 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2022 | 525 | 0.310 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2019 | 1032 | 0.270 |
Why?
|
| Breast Neoplasms | 13 | 2021 | 16242 | 0.260 |
Why?
|
| Neoplasms | 4 | 2020 | 15931 | 0.210 |
Why?
|
| Cell Cycle Proteins | 3 | 2021 | 2112 | 0.210 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2021 | 529 | 0.200 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2015 | 1235 | 0.190 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2021 | 14 | 0.190 |
Why?
|
| Oxadiazoles | 1 | 2021 | 60 | 0.190 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 271 | 0.170 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2021 | 317 | 0.170 |
Why?
|
| PHD Zinc Fingers | 1 | 2019 | 4 | 0.170 |
Why?
|
| Anilides | 1 | 2021 | 295 | 0.160 |
Why?
|
| Metabolome | 1 | 2021 | 353 | 0.160 |
Why?
|
| Benzimidazoles | 1 | 2022 | 437 | 0.160 |
Why?
|
| Histone Code | 1 | 2019 | 85 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 7 | 2011 | 2312 | 0.150 |
Why?
|
| Heterografts | 1 | 2020 | 738 | 0.140 |
Why?
|
| Prognosis | 11 | 2021 | 22520 | 0.140 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 191 | 0.140 |
Why?
|
| Observer Variation | 2 | 2016 | 709 | 0.140 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 242 | 0.140 |
Why?
|
| Biopsy | 2 | 2020 | 3491 | 0.140 |
Why?
|
| Homeodomain Proteins | 2 | 2012 | 1124 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 10402 | 0.130 |
Why?
|
| Piperidines | 1 | 2021 | 1099 | 0.130 |
Why?
|
| beta Catenin | 1 | 2019 | 687 | 0.130 |
Why?
|
| Phthalazines | 1 | 2017 | 262 | 0.130 |
Why?
|
| Receptors, Estrogen | 2 | 2021 | 2177 | 0.130 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 380 | 0.120 |
Why?
|
| Disease Progression | 4 | 2020 | 6867 | 0.120 |
Why?
|
| Pathology, Clinical | 1 | 2016 | 129 | 0.120 |
Why?
|
| Mitotic Index | 1 | 2015 | 162 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 1044 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2021 | 2618 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 528 | 0.120 |
Why?
|
| Female | 24 | 2022 | 148790 | 0.120 |
Why?
|
| Pyridines | 1 | 2021 | 1313 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 2051 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 866 | 0.110 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 31084 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 1901 | 0.110 |
Why?
|
| Cell Proliferation | 4 | 2021 | 7232 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 676 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2019 | 1034 | 0.100 |
Why?
|
| Tissue Array Analysis | 3 | 2015 | 757 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 1089 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 7311 | 0.100 |
Why?
|
| Transcription Factor RelA | 1 | 2012 | 184 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2022 | 3924 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 1656 | 0.100 |
Why?
|
| Histones | 1 | 2019 | 1512 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 5595 | 0.090 |
Why?
|
| Salvage Therapy | 1 | 2019 | 2124 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 1894 | 0.090 |
Why?
|
| Aged | 13 | 2020 | 73534 | 0.090 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 3707 | 0.090 |
Why?
|
| Receptors, Androgen | 1 | 2015 | 854 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2019 | 1385 | 0.090 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2011 | 202 | 0.090 |
Why?
|
| Humans | 27 | 2022 | 270601 | 0.090 |
Why?
|
| Breast | 2 | 2015 | 1370 | 0.090 |
Why?
|
| Middle Aged | 13 | 2020 | 90450 | 0.080 |
Why?
|
| Mice, Nude | 3 | 2022 | 4332 | 0.080 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 3345 | 0.080 |
Why?
|
| Adult | 12 | 2020 | 81960 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 4964 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 3656 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 1260 | 0.080 |
Why?
|
| Cell Line, Tumor | 6 | 2021 | 14876 | 0.080 |
Why?
|
| Estradiol | 1 | 2011 | 828 | 0.080 |
Why?
|
| Carcinoma, Lobular | 1 | 2012 | 622 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 2 | 2007 | 1188 | 0.070 |
Why?
|
| Brachytherapy | 1 | 2014 | 1005 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5417 | 0.070 |
Why?
|
| Apoptosis | 3 | 2021 | 7755 | 0.070 |
Why?
|
| Proto-Oncogenes | 1 | 2006 | 208 | 0.070 |
Why?
|
| Gene Deletion | 1 | 2011 | 1471 | 0.060 |
Why?
|
| Immunohistochemistry | 4 | 2015 | 7643 | 0.060 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 4969 | 0.060 |
Why?
|
| Mice | 6 | 2022 | 35412 | 0.060 |
Why?
|
| Neoplasm Staging | 7 | 2019 | 14021 | 0.060 |
Why?
|
| False Negative Reactions | 1 | 2004 | 291 | 0.060 |
Why?
|
| Young Adult | 2 | 2020 | 22219 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 9047 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2007 | 743 | 0.060 |
Why?
|
| Animals | 7 | 2022 | 61346 | 0.050 |
Why?
|
| Quality Control | 1 | 2004 | 461 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2014 | 3081 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 5318 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 1903 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2004 | 308 | 0.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 2178 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 4966 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2004 | 485 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2022 | 354 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 15270 | 0.050 |
Why?
|
| Male | 5 | 2020 | 128395 | 0.050 |
Why?
|
| Microarray Analysis | 2 | 2012 | 396 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 16719 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 6193 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2021 | 271 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 381 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2021 | 547 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2020 | 33811 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 249 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2012 | 4468 | 0.040 |
Why?
|
| Mitosis | 1 | 2021 | 681 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 589 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 4053 | 0.040 |
Why?
|
| Acrylonitrile | 1 | 2017 | 9 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2022 | 884 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 1355 | 0.040 |
Why?
|
| Mutation | 3 | 2021 | 15905 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2022 | 2419 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 1051 | 0.030 |
Why?
|
| Survival Rate | 3 | 2020 | 12527 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2019 | 578 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2019 | 1023 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2019 | 443 | 0.030 |
Why?
|
| International Agencies | 1 | 2016 | 107 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2017 | 206 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 2343 | 0.030 |
Why?
|
| Cadherins | 1 | 2019 | 659 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 1553 | 0.030 |
Why?
|
| Genes, erbB-1 | 2 | 2006 | 104 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 677 | 0.030 |
Why?
|
| Pathologists | 1 | 2016 | 101 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1825 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 1008 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 5759 | 0.030 |
Why?
|
| Genes, myc | 2 | 2006 | 372 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 369 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 3534 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 1002 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 2478 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 5056 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2017 | 521 | 0.030 |
Why?
|
| Cyclin D1 | 2 | 2005 | 591 | 0.030 |
Why?
|
| Androgens | 1 | 2015 | 506 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2012 | 248 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1101 | 0.020 |
Why?
|
| Caspases, Initiator | 1 | 2011 | 17 | 0.020 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2011 | 71 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 296 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 14638 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2011 | 120 | 0.020 |
Why?
|
| Genotype | 1 | 2019 | 4246 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 1535 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 2832 | 0.020 |
Why?
|
| Protein Folding | 1 | 2011 | 297 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2012 | 251 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 731 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 5144 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2011 | 437 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 622 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 1341 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 762 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 9460 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2019 | 39922 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 2087 | 0.020 |
Why?
|
| Cyclin D | 1 | 2006 | 39 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2006 | 117 | 0.020 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2006 | 125 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 4020 | 0.020 |
Why?
|
| Switzerland | 1 | 2005 | 23 | 0.020 |
Why?
|
| Saudi Arabia | 1 | 2005 | 46 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 2199 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 2028 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2011 | 1610 | 0.020 |
Why?
|
| Cyclins | 1 | 2006 | 465 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2012 | 4907 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 3328 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2006 | 503 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 2458 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 12041 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 17855 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2004 | 822 | 0.010 |
Why?
|
| Epithelium | 1 | 2004 | 786 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6257 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2011 | 2922 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 10267 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2005 | 843 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 1581 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 1958 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 7787 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 2356 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 4317 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2005 | 2376 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 7919 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 9281 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 3435 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 4992 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 5776 | 0.010 |
Why?
|